Trial Profile
A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 May 2010
Price :
$35
*
At a glance
- Drugs Iopofosine I 131 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 05 May 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 05 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2009 Planned end date changed from 1 Dec 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.